<p>極地資產管理公司在最近向證券交易委員會（SEC）提交的文件中表示，在第一季度削減了對 Vertex Pharmaceuticals Incorporated（納斯達克代碼：VRTX - 免費報告）股票的持倉，減幅為 62.1%。該公司在季度內出售了 35,406 股後，持有 21,594 股該製藥公司的股票。極地資產管理公司在 Vertex Pharmaceuticals 的持股在最近一個季度末的價值為 10,469,000 美元。</p>
<ul>
<li>2025 年最佳生物科技股票</li>
</ul>
<p>其他對沖基金和機構投資者最近也買賣了該公司的股票。Aries Wealth Management 在第一季度購買了價值約 293,000 美元的 Vertex Pharmaceuticals 新頭寸。Brighton Jones LLC 在第一季度將其在 Vertex Pharmaceuticals 的持股增加了 45.0%。Brighton Jones LLC 現在擁有 6,421 股該製藥公司的股票，價值 3,113,000 美元，此前在該期間內又收購了 1,994 股。GAMMA Investing LLC 在第一季度將其在 Vertex Pharmaceuticals 的持股增加了 25.1%。GAMMA Investing LLC 現在擁有 5,002 股該製藥公司的股票，價值 2,425,000 美元，此前在該期間內又收購了 1,005 股。Stanley Laman Group Ltd.在第一季度購買了價值約 486,000 美元的 Vertex Pharmaceuticals 新頭寸。最後，Compagnie Lombard Odier SCmA 在第一季度將其在 Vertex Pharmaceuticals 的股份增加了 31.4%。Compagnie Lombard Odier SCmA 現在擁有 12,565 股該製藥公司的股票，價值 6,092,000 美元，此前在該期間內又購買了 3,000 股。目前，90.96% 的股票由對沖基金和其他機構投資者持有。</p>
<p>獲取 <strong>Vertex Pharmaceuticals</strong> 警報：</p>
<h2>Vertex Pharmaceuticals 股票上漲 0.1%</h2>
<p>VRTX 週五開盤價為 396.93 美元。該公司的市值為 1017.7 億美元，市盈率為 28.37，貝塔值為 0.44。Vertex Pharmaceuticals Incorporated 的 52 周最低價為 362.50 美元，52 周最高價為 519.88 美元。該公司的 50 日移動平均線為 429.40 美元，200 日移動平均線為 456.95 美元。</p>
<ul>
<li>MaxCyte：構建細胞和基因治療創新的未來</li>
</ul>
<p>Vertex Pharmaceuticals（納斯達克代碼：VRTX - 獲取免費報告）最近於 8 月 4 日星期一發布了季度財報。該製藥公司報告季度每股收益為 4.52 美元，超出市場共識預期的 4.24 美元，超出幅度為 0.28 美元。該公司季度收入為 29.4 億美元，而分析師預期為 29 億美元。Vertex Pharmaceuticals 的股本回報率為 23.91%，淨利潤率為 31.86%。該公司的收入較去年同期增長了 11.3%。在去年同期，該公司每股收益為（12.83）美元。Vertex Pharmaceuticals 已將其 2025 財年的指引設定為每股收益。股票分析師預計 Vertex Pharmaceuticals Incorporated 在當前財年將發佈 15.63 美元的每股收益。</p>
<h2>華爾街分析師觀點</h2>
<p>VRTX 最近成為幾份研究報告的主題。Stifel Nicolaus 在 8 月 5 日的研究報告中將 Vertex Pharmaceuticals 的目標價從 494.00 美元下調至 455.00 美元，並對該公司給予 “持有” 評級。Wall Street Zen 在 8 月 22 日的研究報告中將 Vertex Pharmaceuticals 的評級從 “強烈買入” 下調至 “買入”。Erste Group Bank 在 5 月 23 日的研究報告中將 Vertex Pharmaceuticals 的評級從 “強烈買入” 下調至 “持有”。Scotiabank 在 8 月 5 日的研究報告中將 Vertex Pharmaceuticals 的目標價從 442.00 美元下調至 438.00 美元，並對該公司給予 “行業表現” 評級。最後，Guggenheim 在 8 月 6 日的研究報告中將 Vertex Pharmaceuticals 的目標價從 558.00 美元下調至 546.00 美元，並對該公司給予 “買入” 評級。一位股票研究分析師對該股票給予了 “強烈買入” 評級，十三位分析師給予 “買入” 評級，另有十三位分析師對該公司的股票給予 “持有” 評級。根據 MarketBeat 的數據，Vertex Pharmaceuticals 的平均評級為 “適度買入”，平均目標價為 497.10 美元。</p>
<ul>
<li>Vertex 的止痛藥：大型製藥公司的下一個重大成功？</li>
</ul>
<p><strong>獲取我們關於 Vertex Pharmaceuticals 的最新股票報告</strong></p>
<h2>內部人士買賣</h2>
<p>在相關消息中，董事 Bruce I. Sachs 在 8 月 6 日星期三購買了 5,000 股該公司的股票。該股票的平均購買價格為 389.68 美元，總交易額為 1,948,400.00 美元。完成購買後，該董事直接持有該公司 45,000 股股票，價值 17,535,600 美元。此交易代表其持股增加了 12.50%。該購買在向證券交易委員會的備案中披露，相關文件可通過此鏈接訪問。目前，0.20% 的股票由公司內部人士持有。</p>
<h2>關於 Vertex Pharmaceuticals</h2>
<p>（免費報告）</p>
<p>Vertex Pharmaceuticals Incorporated 是一家生物技術公司，專注於開發和商業化治療囊性纖維化（CF）的療法。它為至少有一個 F508del 突變的 2 歲或以上的 CF 患者銷售 TRIKAFTA/KAFTRIO；為 6 歲或以上的 CF 患者銷售 SYMDEKO/SYMKEVI；為 1 歲或以上的 CF 患者銷售 ORKAMBI；以及為 1 歲或以上的 CF 患者銷售 KALYDECO。</p>
<h2>閲讀更多</h2>
<ul>
<li>五隻我們更看好的股票超過 Vertex Pharmaceuticals</li>
<li>如何使用 MarketBeat Excel 股息計算器</li>
<li>這裏是 Oklo 與其他核創業公司的區別</li>
<li>現在購買的三隻最佳金融科技股票</li>
<li>為什麼 Marvell 的 19% 下跌可能是一個很好的買入機會</li>
<li>在經濟衰退中與這些股息之王一起度過</li>
<li>Daqo New Energy：太陽能壟斷企業推出 1 億美元回購計劃</li>
</ul>
<p><strong>想知道其他對沖基金持有 VRTX 的情況嗎？</strong> 請訪問 HoldingsChannel.com 獲取 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免費報告) 的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Vertex Pharmaceuticals 嗎？</h2>
<p>在考慮 Vertex Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Vertex Pharmaceuticals 並不在名單上。</p>
<p>雖然 Vertex Pharmaceuticals 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

福泰制藥

<p>Polar Asset Management Partners Inc. 在第一季度減少了對 Vertex Pharmaceuticals (NASDAQ:VRTX) 的持股比例，降幅為 62.1%，目前持有 21,594 股，價值 1,047 萬美元。其他機構投資者也調整了他們的持倉，其中 Brighton Jones LLC 和 GAMMA Investing LLC 的增持尤為顯著。Vertex 的股票開盤價為 396.93 美元，市值為 1,017.7 億美元。該公司報告了第二季度每股收益 (EPS) 為 4.52 美元，超出預期，並已設定 2025 財年的每股收益指導。分析師對該股的評級不一，平均目標價為 497.10 美元</p>

<p>Polar Asset Management Partners Inc. trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 62.1% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,594 shares of the pharmaceutical company's stock after selling 35,406 shares during the quarter. Polar Asset Management Partners Inc.'s holdings in Vertex Pharmaceuticals were worth $10,469,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>極地資產管理公司在最近向證券交易委員會（SEC）提交的文件中表示，在第一季度削減了對 Vertex Pharmaceuticals Incorporated（納斯達克代碼：VRTX - 免費報告）股票的持倉，減幅為 62.1%。該公司在季度內出售了 35,406 股後，持有 21,594 股該製藥公司的股票。極地資產管理公司在 Vertex Pharmaceuticals 的持股在最近一個季度末的價值為 10,469,000 美元。</p>
</div><ul>
<li>Best Biotech Stocks to Buy in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年最佳生物科技股票</li>
</ul>
</div><p>Other hedge funds and other institutional investors also recently bought and sold shares of the company. Aries Wealth Management purchased a new position in Vertex Pharmaceuticals during the 1st quarter valued at about $293,000. Brighton Jones LLC boosted its holdings in Vertex Pharmaceuticals by 45.0% during the 1st quarter. Brighton Jones LLC now owns 6,421 shares of the pharmaceutical company's stock valued at $3,113,000 after acquiring an additional 1,994 shares during the period. GAMMA Investing LLC boosted its holdings in Vertex Pharmaceuticals by 25.1% during the 1st quarter. GAMMA Investing LLC now owns 5,002 shares of the pharmaceutical company's stock valued at $2,425,000 after acquiring an additional 1,005 shares during the period. Stanley Laman Group Ltd. purchased a new position in Vertex Pharmaceuticals during the 1st quarter valued at about $486,000. Finally, Compagnie Lombard Odier SCmA boosted its stake in shares of Vertex Pharmaceuticals by 31.4% in the 1st quarter. Compagnie Lombard Odier SCmA now owns 12,565 shares of the pharmaceutical company's stock valued at $6,092,000 after buying an additional 3,000 shares during the period. 90.96% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他對沖基金和機構投資者最近也買賣了該公司的股票。Aries Wealth Management 在第一季度購買了價值約 293,000 美元的 Vertex Pharmaceuticals 新頭寸。Brighton Jones LLC 在第一季度將其在 Vertex Pharmaceuticals 的持股增加了 45.0%。Brighton Jones LLC 現在擁有 6,421 股該製藥公司的股票，價值 3,113,000 美元，此前在該期間內又收購了 1,994 股。GAMMA Investing LLC 在第一季度將其在 Vertex Pharmaceuticals 的持股增加了 25.1%。GAMMA Investing LLC 現在擁有 5,002 股該製藥公司的股票，價值 2,425,000 美元，此前在該期間內又收購了 1,005 股。Stanley Laman Group Ltd.在第一季度購買了價值約 486,000 美元的 Vertex Pharmaceuticals 新頭寸。最後，Compagnie Lombard Odier SCmA 在第一季度將其在 Vertex Pharmaceuticals 的股份增加了 31.4%。Compagnie Lombard Odier SCmA 現在擁有 12,565 股該製藥公司的股票，價值 6,092,000 美元，此前在該期間內又購買了 3,000 股。目前，90.96% 的股票由對沖基金和其他機構投資者持有。</p>
</div><p>Get <strong>Vertex Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Vertex Pharmaceuticals</strong> 警報：</p>
</div><h2>Vertex Pharmaceuticals Stock Up 0.1%</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 股票上漲 0.1%</h2>
</div><p>VRTX opened at $396.93 on Friday. The firm has a market cap of $101.77 billion, a price-to-earnings ratio of 28.37 and a beta of 0.44. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $519.88. The business's 50 day moving average is $429.40 and its two-hundred day moving average is $456.95.</p>
<div class="lb-trans"><p>VRTX 週五開盤價為 396.93 美元。該公司的市值為 1017.7 億美元，市盈率為 28.37，貝塔值為 0.44。Vertex Pharmaceuticals Incorporated 的 52 周最低價為 362.50 美元，52 周最高價為 519.88 美元。該公司的 50 日移動平均線為 429.40 美元，200 日移動平均線為 456.95 美元。</p>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：構建細胞和基因治療創新的未來</li>
</ul>
</div><p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, topping the consensus estimate of $4.24 by $0.28. The company had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The firm's revenue was up 11.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($12.83) earnings per share. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals（納斯達克代碼：VRTX - 獲取免費報告）最近於 8 月 4 日星期一發布了季度財報。該製藥公司報告季度每股收益為 4.52 美元，超出市場共識預期的 4.24 美元，超出幅度為 0.28 美元。該公司季度收入為 29.4 億美元，而分析師預期為 29 億美元。Vertex Pharmaceuticals 的股本回報率為 23.91%，淨利潤率為 31.86%。該公司的收入較去年同期增長了 11.3%。在去年同期，該公司每股收益為（12.83）美元。Vertex Pharmaceuticals 已將其 2025 財年的指引設定為每股收益。股票分析師預計 Vertex Pharmaceuticals Incorporated 在當前財年將發佈 15.63 美元的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>VRTX has been the subject of several recent research reports. Stifel Nicolaus decreased their price objective on Vertex Pharmaceuticals from $494.00 to $455.00 and set a &#34;hold&#34; rating for the company in a research note on Tuesday, August 5th. Wall Street Zen cut Vertex Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research note on Friday, August 22nd. Erste Group Bank cut Vertex Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Friday, May 23rd. Scotiabank decreased their price objective on Vertex Pharmaceuticals from $442.00 to $438.00 and set a &#34;sector perform&#34; rating for the company in a research note on Tuesday, August 5th. Finally, Guggenheim decreased their price objective on Vertex Pharmaceuticals from $558.00 to $546.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and thirteen have issued a Hold rating to the company's stock. Based on data from MarketBeat, Vertex Pharmaceuticals has an average rating of &#34;Moderate Buy&#34; and an average price target of $497.10.</p>
<div class="lb-trans"><p>VRTX 最近成為幾份研究報告的主題。Stifel Nicolaus 在 8 月 5 日的研究報告中將 Vertex Pharmaceuticals 的目標價從 494.00 美元下調至 455.00 美元，並對該公司給予 “持有” 評級。Wall Street Zen 在 8 月 22 日的研究報告中將 Vertex Pharmaceuticals 的評級從 “強烈買入” 下調至 “買入”。Erste Group Bank 在 5 月 23 日的研究報告中將 Vertex Pharmaceuticals 的評級從 “強烈買入” 下調至 “持有”。Scotiabank 在 8 月 5 日的研究報告中將 Vertex Pharmaceuticals 的目標價從 442.00 美元下調至 438.00 美元，並對該公司給予 “行業表現” 評級。最後，Guggenheim 在 8 月 6 日的研究報告中將 Vertex Pharmaceuticals 的目標價從 558.00 美元下調至 546.00 美元，並對該公司給予 “買入” 評級。一位股票研究分析師對該股票給予了 “強烈買入” 評級，十三位分析師給予 “買入” 評級，另有十三位分析師對該公司的股票給予 “持有” 評級。根據 MarketBeat 的數據，Vertex Pharmaceuticals 的平均評級為 “適度買入”，平均目標價為 497.10 美元。</p>
</div><ul>
<li>Vertex's Pain Drug: Big Pharma's Next Major Success?</li>
</ul>
<div class="lb-trans"><ul>
<li>Vertex 的止痛藥：大型製藥公司的下一個重大成功？</li>
</ul>
</div><p><strong>Get Our Latest Stock Report on Vertex Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Vertex Pharmaceuticals 的最新股票報告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人士買賣</h2>
</div><p>In related news, Director Bruce I. Sachs purchased 5,000 shares of the business's stock in a transaction dated Wednesday, August 6th. The stock was acquired at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the purchase, the director directly owned 45,000 shares of the company's stock, valued at $17,535,600. This trade represents a 12.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. 0.20% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在相關消息中，董事 Bruce I. Sachs 在 8 月 6 日星期三購買了 5,000 股該公司的股票。該股票的平均購買價格為 389.68 美元，總交易額為 1,948,400.00 美元。完成購買後，該董事直接持有該公司 45,000 股股票，價值 17,535,600 美元。此交易代表其持股增加了 12.50%。該購買在向證券交易委員會的備案中披露，相關文件可通過此鏈接訪問。目前，0.20% 的股票由公司內部人士持有。</p>
</div><h2>About Vertex Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Vertex Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals Incorporated 是一家生物技術公司，專注於開發和商業化治療囊性纖維化（CF）的療法。它為至少有一個 F508del 突變的 2 歲或以上的 CF 患者銷售 TRIKAFTA/KAFTRIO；為 6 歲或以上的 CF 患者銷售 SYMDEKO/SYMKEVI；為 1 歲或以上的 CF 患者銷售 ORKAMBI；以及為 1 歲或以上的 CF 患者銷售 KALYDECO。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>閲讀更多</h2>
</div><ul>
<li>Five stocks we like better than Vertex Pharmaceuticals</li>
<li>How to Use the MarketBeat Excel Dividend Calculator</li>
<li>Here's What Separates Oklo From the Rest of the Nuclear Startups</li>
<li>The 3 Best Fintech Stocks to Buy Now</li>
<li>Why Marvell’s 19% Drop Could Be a Big Buy-the-Dip Opportunity</li>
<li>Ride Out The Recession With These Dividend Kings</li>
<li>Daqo New Energy: Solar Monopoly Launches $100M Buyback</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 Vertex Pharmaceuticals</li>
<li>如何使用 MarketBeat Excel 股息計算器</li>
<li>這裏是 Oklo 與其他核創業公司的區別</li>
<li>現在購買的三隻最佳金融科技股票</li>
<li>為什麼 Marvell 的 19% 下跌可能是一個很好的買入機會</li>
<li>在經濟衰退中與這些股息之王一起度過</li>
<li>Daqo New Energy：太陽能壟斷企業推出 1 億美元回購計劃</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding VRTX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他對沖基金持有 VRTX 的情況嗎？</strong> 請訪問 HoldingsChannel.com 獲取 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免費報告) 的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=VRTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Vertex Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Vertex Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Vertex Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Vertex Pharmaceuticals 並不在名單上。</p>
</div><p>While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Vertex Pharmaceuticals 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Polar Asset Management Partners Inc. 減少了在福泰製藥公司 $VRTX 的股票持有量